Hypertonia

2

Review clinical trials related to Hypertonia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Validity and Reliability of the Hypertonia Assessment Tool (HAT) in Stroke Patients

In this study, the validity and reliability of the Hypertonia Assessment Tool (HAT), which has previously been validated in the pediatric cerebral palsy (CP) population, will be evaluated in adult individuals who have experienced a stroke. The HAT is a specific clinical instrument designed to differentiate subtypes of hypertonia, including spasticity, dystonia, and rigidity. Accurate classification of hypertonia subtypes following stroke is crucial for guiding rehabilitation strategies. However, the HAT has not yet been validated in the adult post-stroke population. This study will be conducted at the Physical Medicine and Rehabilitation Clinic of SBU Fatih Sultan Mehmet Training and Research Hospital. The study aims to evaluate the validity and reliability of the HAT for use in adults with stroke.

Participants needed: 60
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Fatih Sultan Mehmet Training and Research HospitalUpdated: Feb 24, 2026Locations: 1
Eligibility criteria

Age 18 years and older [+5]

Age under 18 years [+5]

Status: Recruiting

Turkish Translation , Validity and Reliability of the Hypertonia Assessment Tool in Children With Motor Disorders

Translating batteries with good psychometric properties into Turkish will increase the number of assessment batteries we can use in our language for clinical and academic studies. Therefore, the aim of our study was to verify the validity, reliability, and translation into Turkish of the Hypertonus Assessment Tool for children with motor disorders.

Participants needed: 70
Trial details
Age: Up to 18Biological sex: AllType: ObservationalSponsor: Kastamonu UniversityUpdated: Dec 5, 2025Locations: 1
Eligibility criteria

as voluntary participation in the study, [+2]

Patients with any other systemic disease, [+3]